Onxeo SA, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. More Details
High growth potential with mediocre balance sheet.
Share Price & News
How has Onxeo's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ALONX is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: ALONX's weekly volatility has decreased from 11% to 5% over the past year.
7 Day Return
1 Year Return
Return vs Industry: ALONX exceeded the French Biotechs industry which returned 29.9% over the past year.
Return vs Market: ALONX underperformed the French Market which returned 42.2% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Onxeo's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StOnxeo's (EPA:ALONX) Earnings Are Built On Soft Foundations
2 months ago | Simply Wall StOnxeo (EPA:ALONX) Share Prices Have Dropped 76% In The Last Five Years
4 months ago | Simply Wall StHow Much Did Onxeo's (EPA:ALONX) CEO Pocket Last Year?
Is Onxeo undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ALONX's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ALONX's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ALONX is poor value based on its PE Ratio (45x) compared to the XE Biotechs industry average (31.5x).
PE vs Market: ALONX is poor value based on its PE Ratio (45x) compared to the French market (24x).
Price to Earnings Growth Ratio
PEG Ratio: ALONX is poor value based on its PEG Ratio (1.5x)
Price to Book Ratio
PB vs Industry: ALONX is good value based on its PB Ratio (1.8x) compared to the FR Biotechs industry average (4.4x).
How is Onxeo forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALONX's forecast earnings growth (29.6% per year) is above the savings rate (0.4%).
Earnings vs Market: ALONX's earnings (29.6% per year) are forecast to grow faster than the French market (20.8% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: ALONX's revenue (72.1% per year) is forecast to grow faster than the French market (6.8% per year).
High Growth Revenue: ALONX's revenue (72.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ALONX's Return on Equity is forecast to be high in 3 years time
How has Onxeo performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALONX has a high level of non-cash earnings.
Growing Profit Margin: ALONX became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: ALONX has become profitable over the past 5 years, growing earnings by 9.4% per year.
Accelerating Growth: ALONX has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: ALONX has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (18.9%).
Return on Equity
High ROE: ALONX's Return on Equity (3.8%) is considered low.
How is Onxeo's financial position?
Financial Position Analysis
Short Term Liabilities: ALONX's short term assets (€23.2M) exceed its short term liabilities (€6.0M).
Long Term Liabilities: ALONX's short term assets (€23.2M) exceed its long term liabilities (€11.4M).
Debt to Equity History and Analysis
Debt Level: ALONX's debt to equity ratio (13.8%) is considered satisfactory.
Reducing Debt: ALONX's debt to equity ratio has increased from 0.07% to 13.8% over the past 5 years.
Debt Coverage: ALONX's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if ALONX's interest payments on its debt are well covered by EBIT.
What is Onxeo current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALONX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALONX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALONX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALONX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ALONX's dividend in 3 years as they are not forecast to pay a notable one for the French market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Judith Greciet (52 yo)
Ms. Judith Greciet, Ph.D., Pharmacy, has been the Chief Executive Officer of Onxeo SA (formerly known as BioAlliance Pharma SA) since June 29, 2011. Ms. Greciet served as the Chief Operations Officer - Ope...
CEO Compensation Analysis
Compensation vs Market: Judith's total compensation ($USD553.60K) is above average for companies of similar size in the French market ($USD282.12K).
Compensation vs Earnings: Judith's compensation has been consistent with company performance over the past year.
Experienced Management: ALONX's management team is seasoned and experienced (5.7 years average tenure).
Experienced Board: ALONX's board of directors are considered experienced (3.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 39.9%.
Onxeo SA's company bio, employee growth, exchange listings and data sources
- Name: Onxeo SA
- Ticker: ALONX
- Exchange: ENXTPA
- Founded: 1997
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €61.866m
- Shares outstanding: 91.65m
- Website: https://www.onxeo.com
Number of Employees
- Onxeo SA
- 49, boulevard du GEnEral Martial Valin
Onxeo SA, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of relapsed or refractory perip...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/08 04:09|
|End of Day Share Price||2021/05/07 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.